Tessa Therapeutics Ltd Email Format

Biotechnology ResearchCentral Region, Singapore11-50 Employees

Tessa Therapeutics is a clinical-stage biotechnology company focused on developing next-generation cell therapies for hematological cancers and solid tumors. Its lead program is TT11, an autologous CD30-targeted CAR-T therapy studied as a monotherapy for relapsed or refractory classical Hodgkin lymphoma (Phase 2) and in combination therapy (Phase 1b). The company is also pursuing an allogeneic off-the-shelf platform that augments Epstein-Barr Virus–specific T cells with CD30-CAR, currently in a Phase 1 trial for CD30-positive lymphomas. TT11 has RMAT designation from the U.S. FDA and access to the EMA PRIME scheme. 
Headquartered in Singapore in the Central Region, the company operates a state-of-the-art cell therapy manufacturing facility to support its development programs. Its efforts are directed at patients with Hodgkin lymphoma and other CD30-positive cancers, pursuing both autologous and allogeneic approaches within the oncology market.

Get verified Tessa Therapeutics Ltd emails free

Company overview Employee directory